The EpiPen emergency allergy treatment was pushed into the spotlight last year over concerns about its skyrocketing price and the lack of any real competition for a product that had been around for decades. A new federal lawsuit alleges that Mylan — the company that acquired EpiPen ten years ago — raised its prices in order to provide bigger kickbacks to the companies that help determine which drugs your insurer will and won’t cover. [More]
